Changing boundaries in the treatment of malignant gliomas

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 357-370

  Brandes, Alba A ^a   Basso, Umberto ^a   Pasetto, Lara M ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiogenesis; Chemotherapy; Gene therapy; Glioma; High grade; Nitrosoureas; Radiotherapy; Temozolomide

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 6 O BENZYLGUANINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GOSSYPOL; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; ISOTRETINOIN; MANNITOL; MARIMASTAT; NITROSOUREA; PACLITAXEL; PHENYLACETIC ACID; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ARTHRALGIA; BRAIN TUMOR; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CHEILITIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISORIENTATION; DRUG ELIMINATION; DRUG FORMULATION; DRY SKIN; EDEMA; EXHAUSTION; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; LETHALITY; LUNG TOXICITY; LYMPHOCYTOPENIA; MYALGIA; NAUSEA AND VOMITING; NEUROLOGY; NEUTROPENIA; ONCOLOGY; REVIEW; SENSORY NEUROPATHY; STANDARDIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VALIDATION PROCESS;

EID: 0035557911     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.357     Document Type: Review

References (90)

1. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly
2. Cellular-telephone use and brain tumors
3. Magnetic resonance spectroscopy of brain tumors
4. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment
5. Pathology and Genetics: Tumors of the Nervous system
6. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
7. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of the Radiation Therapy Oncology Group 83-02
8. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Co-operative Group
9. Reoperation in recurrent high-grade gliomas. Literature review of prognostic factors and outcome
10. Current controversies in cancer. Brain radiotherapy in the elderly: Contra
11. Current approaches to radiation therapy for malignant gliomas
12. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma
13. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma
14. Treatment of primary glioblastoma multiforme with standard radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome
15. Phase I trial to determine the safety, pharmacodynamics and pharmacokinetics of RSR13, a novel radioenhancer in newly diagnosed glioblastoma multiforme
16. Boron neutron capture therapy of brain tumors: An emerging therapeutic modality
17. The role of chemotherapy in recurrent malignant gliomas: An overview
18. Response criteria for Phase II studies of supratentorial malignant glioma
19. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
20. Malignant gliomas: Who benefits from adjuvant chemotherapy?
21. A retrospective analysis of post-radiation chemotherapy in 133 patients with glioblastoma multiforme
22. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial
23. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
24. Chemotherapy for adults with malignant glioma
25. Multi-drug versus single agent chemotherapy for high grade astrocytoma: Results of a meta-analysis
26. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic glioma: NCOG 6G61 final report
27. PCV chemotherapy for recurrent glioblastoma multiforme
28. Chemotherapy for anaplastic oligodendroglioma
29. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A Phase II study
30. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults
31. Irinotecan therapy in adults with recurrent or progressive malignant glioma
32. Topotecan treatment of adult with primary malignant glioma
33. A North Central Treatment Group Phase II trial of topotecan in relapsed gliomas
34. A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors
35. Phase II clinical trial in high-grade glioma: Stabilization of disease in patients treated with liposomal doxorubicin
36. KRN8602 (MX2-hydrochloride) an active new agent for the treatment of recurrent high-grade glioma
37. Gossypol treatment of recurrent adult malignant gliomas
38. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report
39. Treatment of recurrent malignant glioma with high dose 13-cis-retinoic acid
40. Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A Phase II study
41. A Phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma
42. The role of paclitaxel in the treatment of primary and metastatic brain tumors
43. Temozolomide in high grade gliomas
44. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
45. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
46. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
47. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A Phase II study
48. Temozolomide chemotherapy in recurrent oligodendroglioma
49. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy
50. Daily temozolomide (TMZ) and concomitant radiation followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme (GBM)
51. 6-metylguanine-DNA-methyltransferase levels with survival of malignant astrocytomas patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study
52. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
53. Procarbazine prior to and concomitant with BCNU in patients with glioblastoma at first relapse: A Phase II study
54. 6-benzylguanine for patients with recurrent or progressive malignant glioma
55. 6-benzylguanine for patients with recurrent or progressive malignant glioma
56. 6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide
57. Multi-institutional trial of BID regimen of temozolomide for recurrent malignant gliomas
58. Protracted daily administration of temozolomide is feasible: A Phase I and pharmacokinetic-pharmacodynamic study
59. Protracted cyclic administration of temozolomide is feasible: A Phase I, pharmacokinetic and pharmacodynamic study
60. Phase I trial of temozolomide using an extended continuous oral schedule
61. Therapy for patients with high grade astrocytoma using intrarterial chemotherapy and radiation therapy
62. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means
63. Safety and efficacy of a Multicenter Study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors
64. Unlocking the blood-brain barrier: A role for RPM-7 in brain tumor therapy
65. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group
66. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group
67. Phase I study of escalating doses of interstitial BCNU administered via wafer in patients with recurrent malignant glioma
68. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study
69. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas
70. Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM)
71. Anti-angiogenic therapy in brain tumor models
72. Development of matrix metalloproteinase inhibitors in cancer therapy
73. A Phase II study of temozolomide (Temodar) plus marimastat for recurrent glioblastoma multiforme (GBM)
74. Human glioma immunobiology in vitro: Implications for immunogene therapy
75. Phase I evaluation of radiation combined with recombinant interferon α-2a and BCNU for patients with high-grade glioma
76. Phase II trial with BCNU plus alpha interferon in patients with recurrent high-grade gliomas
77. Improved long-term survival after intracavitary interleukin-2 lymphokine-activated killer cells for adults with recurrent malignant glioma
78. Systemic T-cell adoptive immunotherapy of malignant gliomas
79. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
80. Targeted toxin therapy for malignant astrocytoma
81. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
82. Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
83. Progress in anti-angiogenic gene therapy of cancer
84. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
85. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
86. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: A pilot study in humans
87. Antisense oligodeoxynucleotide technology: Potential use for the treatment of malignant brain tumors
88. Intravenous administration of ONYX-015, a selective replicating adenovirus, induces antitumoral efficacy
89. Cancer. Has the smart bomb been defused?
90. New drugs in recurrent high grade gliomas